Irisin improves delayed bone repair in diabetic female mice

Area of Science:

• Biomedical Science
• Bone Biology
• Endocrinology

Background:

• Irisin, a myokine derived from fibronectin type II domain-containing 5, influences glucose metabolism.
• Irisin is recognized for its role in connecting muscle and bone.
• Diabetes mellitus can impair bone healing processes.

Purpose of the Study:

• To investigate the efficacy of local irisin administration in improving delayed bone repair in a mouse model of diabetes.
• To compare the effects of local versus systemic irisin delivery on bone healing.
• To explore the underlying mechanisms of irisin's action on bone repair.

Main Methods:

• Streptozotocin (STZ)-induced diabetes model in female mice with induced femoral bone defects.
• Local delivery of irisin using gelatin hydrogel sheets and systemic intraperitoneal injection.
• Quantitative computed tomography (QCT) and histological analyses of femurs.
• Measurement of mRNA levels for bone-related genes (Osterix, chondrogenic, adipogenic).
• In vitro studies using ST2 cells under high-glucose conditions with bone morphogenetic protein-2 (BMP-2).

Main Results:

• Local irisin administration significantly improved delayed femoral bone repair in STZ-induced diabetic mice.
• Local irisin treatment increased Osterix-positive cells at the defect site, indicating enhanced osteoblastic differentiation.
• Systemic (intraperitoneal) irisin injection did not improve bone repair.
• Irisin mitigated the decrease in Osterix mRNA levels caused by advanced glycation end products or high-glucose conditions in vitro.

Conclusions:

• Local administration of irisin via gelatin hydrogel sheets effectively enhances delayed bone repair in a diabetic state.
• The mechanism involves, in part, the promotion of osteoblastic differentiation.
• This study highlights the potential of localized irisin therapy for bone regeneration in diabetic patients.